Zai Lab Balance Sheet Health
Financial Health criteria checks 4/6
Zai Lab has a total shareholder equity of $762.2M and total debt of $48.3M, which brings its debt-to-equity ratio to 6.3%. Its total assets and total liabilities are $988.4M and $226.3M respectively.
Key information
6.3%
Debt to equity ratio
US$48.27m
Debt
Interest coverage ratio | n/a |
Cash | US$650.78m |
Equity | US$762.17m |
Total liabilities | US$226.27m |
Total assets | US$988.44m |
Recent financial health updates
We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Sep 19Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth
Jun 03Recent updates
Shareholders May Not Be So Generous With Zai Lab Limited's (NASDAQ:ZLAB) CEO Compensation And Here's Why
Jun 12Improved Revenues Required Before Zai Lab Limited (NASDAQ:ZLAB) Stock's 50% Jump Looks Justified
May 14A Risky Bet: Zai Lab's Uncertain Future
Apr 16Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Mar 29We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S
Jan 18Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 24We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?
Feb 16Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Sep 19Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M
Aug 09China accepts Zai Lab's biologics license application for neuromuscular disorder drug
Jul 13Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth
Jun 03As Losses Narrow, Is Zai Lab Finally Finding Its Winning Formula?
May 18Financial Position Analysis
Short Term Liabilities: ZLAB's short term assets ($888.6M) exceed its short term liabilities ($192.1M).
Long Term Liabilities: ZLAB's short term assets ($888.6M) exceed its long term liabilities ($34.2M).
Debt to Equity History and Analysis
Debt Level: ZLAB has more cash than its total debt.
Reducing Debt: ZLAB's debt to equity ratio has increased from 1.5% to 6.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZLAB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ZLAB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.